Logo

Novo Nordisk Signs ActiveSight for Protein Crystallography

Jan 23, 2006

NEW YORK, Jan. 23 (GenomeWeb News) - ActiveSight has signed a deal with Novo Nordisk to provide protein crystallography, the company announced today.

 

Terms of the agreement were not disclosed.

 

ActiveSight is a division of Rigaku that features a portfolio of drug targets for co-crystallography.

Breaking News
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.